Phase I study of temozolomide in paediatric patients with advanced cancer
1998

Temozolomide in Children with Advanced Cancer

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): EJ Estlin, L Lashford, S Ablett, L Price, R Gowing, A Gholkar, J Kohler, IJ Lewis, B Morland, CR Pinkerton, MCG Stevens, M Mott, R Stevens, DR Newell, D Walker, C Dicks-Mireaux, H McDowell, P Reidenberg, P Statkevich, A Marco, V Batra, M Dugan, ADJ Pearson

Primary Institution: University of Leicester

Hypothesis

What is the maximum-tolerated dose (MTD) and safety profile of temozolomide in pediatric patients with advanced cancer?

Conclusion

The maximum-tolerated dose of temozolomide in children without prior craniospinal irradiation or nitrosourea therapy is 1000 mg/m² per cycle, with myelosuppression as the dose-limiting toxicity.

Supporting Evidence

  • Two out of five patients with high-grade astrocytomas showed responses.
  • One patient with diffuse intrinsic brain stem glioma achieved a long-term partial response.
  • Thrombocytopenia was the main dose-limiting toxicity observed.

Takeaway

This study tested a cancer drug called temozolomide in kids with serious cancers to find out how much they can safely take and how it affects them.

Methodology

The study involved administering temozolomide orally for 5 consecutive days to pediatric patients and evaluating their responses and side effects.

Potential Biases

Potential bias due to the small sample size and the nature of the study design.

Limitations

The study had limited recruitment for patients with prior craniospinal irradiation, affecting the ability to define the MTD for that group.

Participant Demographics

Patients were aged less than 18 years, with a majority diagnosed with primary central nervous system tumors.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication